Adequan, NSAIDs, anti-NGF therapy and supplements: how options differ

Adequan Canine: a prescription PSGAG injection

Adequan Canine contains polysulfated glycosaminoglycan and is FDA-approved for intramuscular use in dogs for control of signs associated with non-infectious degenerative or traumatic arthritis of synovial joints. It is given under veterinary direction on a labeled treatment schedule.

Because product status can change, check the current label and FDA notices. In August 2026, FDA posted a recall involving specified lots due to visible glass-fiber material; pet owners should verify lot information with their veterinarian or pharmacy rather than stopping prescribed care without guidance.

Veterinary NSAIDs: pain and inflammation control

Veterinary NSAIDs affect prostaglandin pathways involved in pain and inflammation. Several are FDA-approved for canine osteoarthritis. The veterinarian considers gastrointestinal, kidney, liver, bleeding, hydration, other medications, and the dog’s overall health.

Do not combine NSAIDs, or combine an NSAID with a steroid, unless the prescribing veterinarian explicitly manages the plan. Baseline and follow-up testing may be recommended for long-term use.

Anti-NGF therapy: a different pain pathway

Librela, or bedinvetmab, is an FDA-approved dog-specific monoclonal antibody that binds nerve growth factor and is labeled to control pain associated with osteoarthritis in dogs. It is administered by a veterinarian on a monthly schedule.

Review the current client information sheet and discuss post-approval safety information, other medications, neurologic or mobility history, and what changes should prompt a call. The current label states that safe concurrent use with NSAIDs has not been established in dogs.

Supplements and everyday care

Supplements are a broad category. AAHA’s pain guidance reports stronger evidence for omega-3 fatty acids in dogs than for many other nutraceuticals. Product composition, dose, calories, interactions, and quality still matter.

Lean body condition, appropriate movement, rehabilitation, traction, sleep, and a realistic activity plan are not “extras.” They help determine how well the complete plan supports function.

Questions that make the comparison useful

• What diagnosis and pain pattern are we treating?
• Which option targets pain, inflammation, joint environment, or function?
• What contraindications, interactions, and monitoring apply to this dog?
• What is the expected timeframe, and which home measures will we track?
• Can these options be combined safely, or should they be sequenced?
• When should rehabilitation or surgical referral enter the plan?